Transcription–replication conflicts underlie sensitivity to PARP inhibitors
Nature · 11.04.2024 · 628 (8007) · 433-441
DOI: 10.1038/s41586-024-07217-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nature, online erschienen am 20.03.2024. Verfasst von Michalis Petropoulos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biology, University of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: DNA Replication, Poly(ADP-ribose) Polymerase Inhibitors, Poly(ADP-ribose) Polymerases, Transcription, Genetic. Die Arbeit wurde bisher 219-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, University of Geneva.
Abstract (Originalsprache)
An important advance in cancer therapy has been the development of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of homologous recombination (HR)-deficient cancers 1–6 . PARP inhibitors trap PARPs on DNA. The trapped PARPs are thought to block replisome progression, leading to formation of DNA double-strand breaks that require HR for repair 7 . Here we show that PARP1 functions together with TIMELESS and TIPIN to protect the replisome in early S phase from transcription–replication conflicts. Furthermore, the synthetic lethality of PARP inhibitors with HR deficiency is due to an inability to repair DNA damage caused by transcription–replication conflicts, rather than by trapped PARPs. Along these lines, inhibiting transcription elongation in early S phase rendered HR-deficient cells resistant to PARP inhibitors and depleting PARP1 by small-interfering RNA was synthetic lethal with HR deficiency. Thus, inhibiting PARP1 enzymatic activity may suffice for treatment efficacy in HR-deficient settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cellular Biology, University of Geneva, Geneva, Switzerland.
- FoRx Therapeutics AG, Basel, Switzerland.
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
- Department of Molecular and Cellular Biology, University of Geneva, Geneva, Switzerland. thanos.halazonetis@unige.ch.
ORCID-Profile: Giacomo G Rossetti, Thanos D Halazonetis
Förderung
- Swiss National Science Foundation
- University of Geneva
Zitieren
APA
Petropoulos, M., Karamichali, A., Rossetti, G. G., Freudenmann, A., Iacovino, L. G., Dionellis, V. S., Sotiriou, S. K., & Halazonetis, T. D. (2024). Transcription–replication conflicts underlie sensitivity to PARP inhibitors. Nature, 628(8007), 433-441. https://doi.org/10.1038/s41586-024-07217-2
Vancouver
Petropoulos M, Karamichali A, Rossetti GG, Freudenmann A, Iacovino LG, Dionellis VS, et al. Transcription–replication conflicts underlie sensitivity to PARP inhibitors. Nature. 2024;628(8007):433-441. doi:10.1038/s41586-024-07217-2
BibTeX
@article{Petropoulos2024,
author = {Petropoulos, Michalis and Karamichali, Angeliki and Rossetti, Giacomo G and Freudenmann, Alena and Iacovino, Luca G and Dionellis, Vasilis S and Sotiriou, Sotirios K and Halazonetis, Thanos D},
title = {Transcription–replication conflicts underlie sensitivity to PARP inhibitors},
journal = {Nature},
year = {2024},
volume = {628},
number = {8007},
pages = {433--441},
doi = {10.1038/s41586-024-07217-2}
}
EUVIMED